Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) – Seeking Alpha

Written by

admin

in

  1. Regenxbio: Remains A “Buy Rating” Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX)  Seeking Alpha
  2. Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date  Yahoo Finance
  3. Goldman Sachs reiterates Neutral rating on Regenxbio stock at $14 target  Investing.com
  4. 82% Brain Disease Marker Drop: REGENXBIO’s One-Time Hunter Syndrome Treatment Shows Promise in Pivotal Trial  Stock Titan
  5. Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its review  Endpoints News

Continue Reading

More posts